Search research articles
Contact Us
Filters
Showing results (81-90 of 143) with videos related to
Page
of 15
Sort By:
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
Cediranib for metastatic alveolar soft part sarcoma
Shivaani Kummar, Deborah Allen, Anne Monks, et al.
Cancer Chemotherapy and Pharmacology
|
September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
Ramesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Leukemia & Lymphoma
|
March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W L Yee, John M Storring, Rena Buckstein, et al.
Cancer Research Communications
|
March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
American Heart Journal
|
February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Richard M Steingart, George L Bakris, Helen X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
Suresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
Brenda J Weigel, Susan M Blaney, Joel M Reid, et al.
Journal of the National Cancer Institute
|
March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Michael L Maitland, George L Bakris, Henry R Black, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 143) with videos related to
Sort By:
Page
of 15
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
Cediranib for metastatic alveolar soft part sarcoma
Shivaani Kummar, Deborah Allen, Anne Monks, et al.
Cancer Chemotherapy and Pharmacology
|
September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
Ramesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Leukemia & Lymphoma
|
March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W L Yee, John M Storring, Rena Buckstein, et al.
Cancer Research Communications
|
March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
American Heart Journal
|
February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Richard M Steingart, George L Bakris, Helen X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
Suresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
Brenda J Weigel, Susan M Blaney, Joel M Reid, et al.
Journal of the National Cancer Institute
|
March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Michael L Maitland, George L Bakris, Henry R Black, et al.
Page
of 15